Erasca Inc. Common Stock vs Edgewise Therapeutics Inc. Common Stock — how do they compare? Erasca Inc. Common Stock trades at $14.6 (market cap $5.17B), while Edgewise Therapeutics Inc. Common Stock trades at $37.11 (market cap $3.94B). The key difference: Erasca Inc. Common Stock is the larger of the two by market cap, and Edgewise Therapeutics Inc. Common Stock is more actively traded (810,104 versus 5,313,379). Which is the better fit depends on your goals — on Pluang, investors hold Erasca Inc. Common Stock for 1 Days and Edgewise Therapeutics Inc. Common Stock for 0 Days on average.
| ERAS | EWTX | |
|---|---|---|
Market Cap | $5.17B | $3.94B |
Volume | 5,313,379 | 810,104 |
Sector | Health | Health |
52-Week High | $22.47 | $48.35 |
52-Week Low | $2.20 | $14.89 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $4.95B | $3.48B |
Signals from Pluang's Aura AI — not financial advice
ERAS trades at $14.78, down 4.4% today, with a bullish technical signal from moving averages and a consensus analyst price target of $22.50. The company is a clinical-stage oncology firm with no revenue, reporting a net loss of $124.55 million in 2025, but holds significant liquidity and has three potential registration-enabling trials ahead. Recent news highlights FDA Fast Track designation for its lead candidate ERAS-0015.
The outlook is speculative, driven by clinical trial progress; upside exists if trials succeed, but high cash burn and shareholder investigations pose substantial risks. Investment hinges on binary outcomes from drug development, making it suitable only for risk-tolerant investors focused on biotech.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Erasca is a biotechnology company developing precision medicines for cancer. Its programs target genetic drivers of tumor growth.
Read more on ERAS →Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →